Loading clinical trials...
Loading clinical trials...
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)
Conditions
Interventions
AAA617
Locations
142
United States
Highlands Oncology Group
Fayetteville, Arkansas, United States
VA Greater LA Healthcare System
Los Angeles, California, United States
VA Palo Alto Health Care System
Palo Alto, California, United States
Stanford University
Palo Alto, California, United States
UCSF
San Francisco, California, United States
Rocky Mountain Cancer Centers
Denver, Colorado, United States
Start Date
March 12, 2024
Primary Completion Date
April 25, 2028
Completion Date
October 3, 2031
Last Updated
April 16, 2026
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions